Scholarlink

<p>Live attenuated and vero-cell-inactivated Japanese Encephalitis vaccines (LJEV, IJEV) have been in common use in young children in China since 1989 and 2004, associated with large reductions in Japanese encephalitis (JE) incidence. In 2013, northern China reported JE outbreaks among adults born before JE vaccine availability, a trend that worsened in 2017–2018. We conducted an open-label, randomized, controlled trial (ChiCTR2500103235) to assess the immunogenicity, immune persistence, and safety of three JE vaccine schedules in 40–69-year-olds to provide evidence for adult targeted JE immunization efforts. Outcomes were seroconversion proportions and seropositive prevalences; adverse events were monitored. The vaccines were immunogenic with no significant difference between vaccination groups. Seropositivity remained above 80% at one year post-vaccination. No serious adverse events occurred. All three schedules had good, persistent immunogenicity and favorable safety profiles in 40–69-year-old adults, providing evidence supporting vaccinating adults in response to the emergence of adult JE in northern China.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunogenicity, immune persistence, and safety of japanese encephalitis vaccine schedules among adults in Ningxia, China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月30日

查看全文
  • Dan Wu,
  • Qikai Yin,
  • Ying Zhang,
  • Yixing Li,
  • Liwei Zhou,
  • Shihong Fu,
  • Xue Li,
  • Hui Zheng,
  • Yiqun Wu,
  • Luping Zhou,
  • Qian Zhang,
  • Mingshuang Li,
  • Tingting Yan,
  • Xueying Qin,
  • Lance Rodewald,
  • Junhui Wu,
  • Yanru Sun,
  • Zhijie An,
  • Zundong Yin,
  • Huanyu Wang,
  • Yonghua Hu

摘要

Live attenuated and vero-cell-inactivated Japanese Encephalitis vaccines (LJEV, IJEV) have been in common use in young children in China since 1989 and 2004, associated with large reductions in Japanese encephalitis (JE) incidence. In 2013, northern China reported JE outbreaks among adults born before JE vaccine availability, a trend that worsened in 2017–2018. We conducted an open-label, randomized, controlled trial (ChiCTR2500103235) to assess the immunogenicity, immune persistence, and safety of three JE vaccine schedules in 40–69-year-olds to provide evidence for adult targeted JE immunization efforts. Outcomes were seroconversion proportions and seropositive prevalences; adverse events were monitored. The vaccines were immunogenic with no significant difference between vaccination groups. Seropositivity remained above 80% at one year post-vaccination. No serious adverse events occurred. All three schedules had good, persistent immunogenicity and favorable safety profiles in 40–69-year-old adults, providing evidence supporting vaccinating adults in response to the emergence of adult JE in northern China.